ORLANDO, Fla., March 9 -- SurgiLight Inc. announced that it would begin Human Phase I clinical studies using its IR-3000 laser for Laser Presbyopia Reversal (LPR) in Spain within a month. Presbyopia is a visual condition in which loss of elasticity of the lens of the eye causes defective accommodation and inability to focus sharply for near vision.
   The company has received Institutional Review Board (IRB) approval at the Department of Ophthalmology, Institute Universitari Dexus, where Carlos Verges will perform this Phase I clinical study on a total of ten eyes. This clinical study follows the initiation of the baseline studies and research at the University of Utah Health and Sciences Center, John A. Moran Eye Center. Nick Mamalis began the baseline study in February and the preliminary results from these studies have been promising, said SurgiLight.